Immunoglobulins in the treatment of Guillain-Barré syndrome in early childhood.
This is a prospective study on the use of immunoglobulins in the treatment of Guillain-Barré syndrome in four children, three of whom were younger than 3 years of age. All of them were unable to walk and were still deteriorating when the treatment was started. Three patients started recovering within 24 hours, and all the patients were fully mobile within 6 weeks after receiving first dose of immunoglobulins. This report shows the efficacy of intravenous immunoglobulins in the treatment of young children presenting with acute Guillain-Barré syndrome.
al-Qudah
A A
AA
Department of Pediatrics, Jordan University Hospital, Amman, Jordan.
D002648:Child; D002675:Child, Preschool; D003391:Cranial Nerves / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007116:Immunization, Passive; D007223:Infant; D008297:Male; D009460:Neurologic Examination; D011129:Polyradiculoneuropathy / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D012008:Recurrence; D012026:Reflex, Stretch / Q000502:physiology